EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
06 févr. 2024 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
invivyd-logo.jpg
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05 févr. 2024 16h02 HE | Invivyd
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
New APA Poll: One in
New APA Poll: One in Three Americans Feels Lonely Every Week
30 janv. 2024 10h00 HE | American Psychiatric Association
Washington, D.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- In May 2023, U.S. Surgeon General Vivek Murthy, M.D., M.B.A., called loneliness a public health epidemic. The latest Healthy Minds Monthly Poll...
InflaRx on large white.jpg
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25 janv. 2024 07h30 HE | InflaRx N.V.
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for...
The Association of American Physicians and Surgeons Educational Foundation Challenges Censorship
18 déc. 2023 12h55 HE | Association of American Physicians and Surgeons
AAPS Educational Foundation challenges censorship imposed by revoking physicians' board certification, and the Biden regime's Disinformation board.
To Save the Profession, Physicians Must Learn from the COVID Response, States AAPS President
12 déc. 2023 12h41 HE | Association of American Physicians and Surgeons
The extreme measures responding to COVID, which was treated as a national security, not a public health issue, caused great harm. Doctors must speak out.
revive-therapeutics.png
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
06 nov. 2023 07h45 HE | Revive Therapeutics Ltd.
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd....
Dyadic Logo Current.jpg
Dyadic to Present at Industry Events in November
30 oct. 2023 08h30 HE | Dyadic International, Inc.
Dyadic to Present at Industry Events in November
Dyadic Logo Current.jpg
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
05 oct. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
18 sept. 2023 16h16 HE | Sixty Degrees Pharmaceuticals
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use...